Rabies Vaccine (HDCV/PCECV/PVRV)

Vaccine Entry · Atlas Four

Inactivated Whole-Virion · BPL-Inactivated · Rabies Prophylaxis (Pre- and Post-Exposure)

Rabies vaccines are inactivated whole-virion preparations of rabies virus grown in cell culture (human diploid, chick embryo, or Vero cells), inactivated with beta-propiolactone, and used for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). When administered correctly with rabies immunoglobulin (RIG) on Day 0, PEP is virtually 100% effective — yet rabies kills ~59,000 people annually, almost entirely because of delayed or absent access to post-exposure care.

HDCV (Imovax) PCECV (RabAvert) PVRV (Verorab) Rabies Immune Globulin (RIG) — co-admin Day 0

Overview

Rabies remains one of the world's most lethal infectious diseases, with a case fatality rate approaching 100% once clinical signs appear. The causative agent, Rabies lyssavirus (RABV), travels centripetally along peripheral motor and sensory axons at 50–100 mm/day after inoculation, crossing into the CNS before reaching the brain, where it causes a rapidly fatal encephalitis. This slow axonal transport creates a critical window during which post-exposure prophylaxis — consisting of wound washing, vaccine, and rabies immunoglobulin — can intercept the virus before CNS entry. The three main licensed vaccine platforms are: HDCV (Human Diploid Cell Vaccine, MRC-5 cells; Imovax — Sanofi Pasteur), PCECV (Purified Chick Embryo Cell Vaccine; RabAvert — Bavarian Nordic/GSK), and PVRV (Purified Vero-cell Rabies Vaccine; Verorab — Sanofi). All use β-propiolactone (BPL) to inactivate either the CVS or Pitman-Moore strain of rabies virus.

The correlate of protection is a virus-neutralizing antibody (VNA) titer ≥0.5 IU/mL as measured by the Rapid Fluorescent Focus Inhibition Test (RFFIT) or Fluorescent Antibody Virus Neutralization (FAVN) assay. Greater than 99% of immunocompetent individuals reach this threshold after a completed primary pre-exposure or post-exposure series. Rabies vaccines appear on the WHO Essential Medicines List and are subject to WHO prequalification (Verorab and others). Pre-exposure prophylaxis (PrEP) protects high-risk professionals and travelers and simplifies post-exposure management to 2 booster doses without RIG.

Despite effective vaccines existing since the 1970s (Wiktor 1964 HDCV development; WHO position papers 1973–2018), rabies kills approximately 59,000 people per year globally (Hampson 2015), predominantly in Asia and Africa, and predominantly in children bitten by dogs. This toll reflects not vaccine failure but a prevention gap: lack of affordable vaccine access, inadequate canine vaccination programs, and the high cost and scarcity of rabies immunoglobulin (RIG) in low-income settings. The 2018 WHO position paper endorsed a simplified 2-dose PrEP schedule (Day 0 and Day 7) replacing the earlier 3-dose schedule, increasing feasibility of mass pre-exposure coverage.

Platform & Antigen Design

INACTIVATED RABIES VACCINE — MANUFACTURE & PEP MECHANISM
==========================================================

  MANUFACTURE:
  Rabies virus (CVS or Pitman-Moore strain)
  grown in MRC-5 / chick embryo / Vero cells
          │
          ▼
  Harvest → clarification → concentration
          │
          ▼
  β-Propiolactone (BPL) inactivation
  [alkylates viral nucleic acid; preserves G protein]
          │
          ▼
  Purification → adjuvant-free formulation (HDCV/PCECV)
  or alum-adjuvanted (PVRV)

  POST-EXPOSURE RACE AGAINST AXONAL TRANSPORT:
  Bite site (peripheral nerve)
          │ Virus travels retrogradely
          │ ~50–100 mm/day centripetal
          │
          ▼
  Vaccine + RIG given Day 0 (wound site)
  → Passive neutralization by RIG at entry point
  → Active immunity building (VNA detectable ~Day 7–14)
  → Antibody reaches CNS-ward viral front
          │
          ▼
  If VNA ≥0.5 IU/mL before viral CNS entry → survival
  If viral entry to CNS before immune response → fatal encephalitis

Cell culture propagation: Rabies virus (CVS or Pitman-Moore strain) is grown to high titer in MRC-5 human diploid cells (HDCV), chick embryo cells (PCECV), or Vero cells (PVRV); cells are lysed and virus harvested after peak replication.
BPL inactivation: β-Propiolactone alkylates viral RNA, rendering the virus non-replicative while preserving the glycoprotein (G protein) antigen — the primary target for virus-neutralizing antibodies and T-cell responses.
Purification: Zonal centrifugation and/or column chromatography removes cellular debris and concentrates inactivated virions. HDCV and PCECV are adjuvant-free; PVRV uses aluminum phosphate adjuvant in some formulations.
VNA production: After IM injection, inactivated virions are phagocytosed by APCs → CD4⁺ T-cell priming → B-cell activation → VNA (predominantly anti-G-protein IgG) detectable by Day 7–14; peak titer by Day 28–35.
PEP window: The critical principle is that rabies virus travels centripetally along axons at ~50–100 mm/day. This slow transport gives a window (hours to days) in which RIG (passive) plus vaccine (active) can generate neutralizing antibody before the virus crosses into the CNS — after which clinical rabies is uniformly fatal.

Immunogenicity

Humoral Response

Anti-G-protein IgG (VNA) is the dominant protective response. VNA ≥0.5 IU/mL (RFFIT/FAVN) achieved in >99% of immunocompetent adults after 3-dose PrEP or completed PEP series. Titers peak at Day 28–35 post-series initiation and may persist ≥2 years. Memory B cells allow rapid booster anamnestic responses in previously vaccinated individuals exposed again (only 2 doses needed, no RIG).

CD4⁺ / CD8⁺ T-Cell Response

Th1-skewed CD4⁺ T-cell responses (IFN-γ, IL-2) against rabies nucleoprotein (N) and glycoprotein (G) epitopes contribute to long-term memory. CD8⁺ cytotoxic T cells play a secondary role; their importance is emphasized in murine models. T-cell memory provides the cellular basis for rapid VNA anamnestic response upon booster or re-exposure.

Innate Activation

Inactivated whole-virion preparations activate pattern recognition receptors including TLR7/8 (single-stranded viral RNA remnants) and TLR2/4, triggering modest innate activation (IL-6, TNF-α, type-I IFN). Alum adjuvant (PVRV) provides additional depot effect and NLRP3 inflammasome activation. Overall reactogenicity is lower than live vaccines.

Duration / Durability

VNA titers wane over years; however, immunological memory is robust. WHO previously recommended 10-year PrEP boosters for ongoing-risk occupations; 2018 position paper deferred serological booster decision to national programs. Travelers with completed PrEP series can receive 2-dose simplified PEP without RIG, even years later, due to memory B-cell persistence. Immunosuppressed individuals may require serological monitoring.

Clinical Efficacy

Context / Study	Design	n / Exposure	Primary Endpoint	Outcome
PEP — Essen regimen (historic)	Observational; WHO-standardized protocol (Day 0/3/7/14/28, IM + RIG Day 0)	Thousands of bite-exposed cases globally	Survival after confirmed rabid animal exposure	~100% when initiated promptly and correctly (Rupprecht 2010)
PrEP — Controlled efficacy (Wiktor 1980)	Seroconversion study; HDCV 3-dose IM primary series	~100 healthy adults	VNA ≥0.5 IU/mL at Day 35	100% seroconversion; titer mean ~11 IU/mL
PrEP 2-dose (WHO 2018)	Non-inferiority immunogenicity; Day 0+7 vs. Day 0+7+21	~800 participants (pooled)	VNA ≥0.5 IU/mL at Day 28	≥98% seroconversion; non-inferior to 3-dose (WHO/IVB/17.01)
Zagreb PEP regimen	2-dose IM Day 0 (both deltoids) + 1 dose Day 7 + 1 dose Day 21; alternative to Essen	Comparative immunogenicity	VNA ≥0.5 IU/mL kinetics	Equivalent immunogenicity; faster peak (Day 14 vs. 28)
Hampson et al. 2015 (burden)	Systematic review / global burden modeling	Global surveillance data	Annual rabies deaths globally	~59,000 deaths/year; 99% preventable with PEP access

Safety Profile

Rare / Serious Serum sickness-like reaction (HDCV, boosters) — Immune-complex hypersensitivity (Type III) reported in ~6% of adults receiving HDCV booster doses; mediated by altered human albumin (HSA) in HDCV formulation interacting with anti-HSA antibodies from prior doses. Presents with urticaria, arthralgia, angioedema 2–21 days post-booster. Risk lower with PCECV/PVRV. Incidence after primary series <0.1%.
Rare / Serious Anaphylaxis — Very rare; estimated ~1–3 per 100,000 doses. Requires immediate epinephrine. Do not discontinue PEP course for anaphylaxis — switch to PCECV if HDCV-mediated, continue under medical supervision.
Rare / Serious Neurological events (historical) — Rare Guillain-Barré-like syndrome reported with older nerve tissue vaccines (now discontinued). Not reported with modern cell-culture vaccines at significant frequency.
Common Injection-site pain, erythema, swelling — 30–74% of recipients; localized, self-limiting within 24–48 hours.
Common Systemic reactions — Headache (~5%), nausea, dizziness, abdominal pain; reported in 5–40% of recipients depending on regimen. More common with intradermal (ID) route.
Uncommon Fever — Low-grade (<38.5 °C) in <5% of recipients; self-limited. Higher rates in children.
Note — RIG co-administration Rabies immunoglobulin (hRIG or eRIG) — RIG (human or equine) given Day 0 at/around wound site has its own safety profile: local pain, rare serum sickness (eRIG ~0.7%). Human RIG (hRIG) preferred. Equine RIG (eRIG) requires skin testing.

Administration

Parameter	Details
PrEP Schedule	2-dose (WHO 2018): Day 0 and Day 7 IM (deltoid). Older 3-dose: Day 0, 7, 21 or 28. For ongoing risk, booster per national guidance or serology (VNA <0.5 IU/mL triggers booster).
PEP — Essen	5-dose: Days 0, 3, 7, 14, 28 IM. Plus RIG (20 IU/kg hRIG or 40 IU/kg eRIG) infiltrated into and around wound Day 0. If prior vaccinated: 2-dose Day 0 + 3 (or 0 + 7), no RIG.
PEP — Zagreb	4-dose: Day 0 ×2 (one each deltoid), Day 7, Day 21. Plus RIG Day 0. Equivalent immunogenicity to Essen; fewer clinic visits.
Route	IM (deltoid); never gluteal (reduces immunogenicity). Intradermal (ID) regimens used in resource-limited settings to reduce dose/cost — WHO-approved for cell-culture vaccines.
Storage	2–8 °C. Do not freeze. Use reconstituted vaccine immediately (lyophilized formulations). Standard cold chain; widely available globally.
Wound care	Thorough wound washing with soap and water for ≥15 minutes + virucidal agent (povidone-iodine or 70% ethanol) is an independent life-saving step — reduces viral load at entry site before immune system is engaged.
Contraindications	PEP: NO absolute contraindications — risk of fatal rabies outweighs all risks. PrEP: history of severe hypersensitivity to vaccine components. Pregnancy is NOT a contraindication for PEP.

Connections

Immune System B Cell T Helper Cell Antibody (IgG) Nervous System Peripheral Nerve Axonal Transport Dendritic Cell Zoonosis Tetanus Toxoid

References

Hampson K, et al. Estimating the Global Burden of Endemic Canine Rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709. doi:10.1371/journal.pntd.0003709
Fooks AR, et al. Current status of rabies and prospects for elimination. Lancet. 2014;384(9951):1389–1399. doi:10.1016/S0140-6736(13)62707-5
WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec. 2018;93(16):201–220. WHO/IVB/17.01. WHO WER 2018
Rupprecht CE, et al. Rabies re-examined. Lancet Infect Dis. 2002;2(6):327–343. PMID 12144896
Wiktor TJ, et al. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev Biol Stand. 1978;40:3–9. PMID 357997
Shantavasinkul P, Wilde H. Failure of rabies postexposure prophylaxis in patients presenting with incubating rabies. Curr Infect Dis Rep. 2012;14(3):242–248. PMID 22399285